CRISPR Therapeutics AG

For the period ended Dec 31, 2023. Filed Feb 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 21, 2024

CRSP$45.15-9.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive (Loss)

Consolidated Statements of Operations and Comprehensive (Loss) Income

(In thousands, except share and per share data)

	Years Ended December 31,
	2023	2022	2021
Revenue:
Collaboration revenue	$370,000	$436	$913,081
Grant revenue	1,206	762	1,882
Total revenue	371,206	1,198	914,963
Operating expenses:
Research and development	387,332	461,645	340,567
General and administrative	76,162	102,464	99,690
Collaboration expense, net	130,250	110,250	101,178
Total operating expenses	593,744	674,359	541,435
(Loss) income from operations	(222,538)	(673,161)	373,528
Other income:
Other income, net	71,816	22,661	6,003
Total other income, net	71,816	22,661	6,003
Net (loss) income before income taxes	(150,722)	(650,500)	379,531
(Provision) benefit for income taxes	(2,888)	325	(1,870)
Net (loss) income	(153,610)	(650,175)	377,661
Foreign currency translation adjustment	73	(80)	(11)
Unrealized gain (loss) on marketable securities	17,487	(10,500)	(4,973)
Comprehensive (loss) income	$(136,050)	$(660,755)	$372,677
Net (loss) income per common share — basic	$(1.94)	$(8.36)	$4.97
Basic weighted-average common shares outstanding	79,220,930	77,746,575	75,948,686
Net (loss) income per common share — diluted	$(1.94)	$(8.36)	$4.70
Diluted weighted-average common shares outstanding	79,220,930	77,746,575	80,393,496

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.